Search results for PTXCOV-A514

Anti-2019-nCoV(S1) – 2 (H4) antibody, ProteoGenix, PTXCOV-A514

Description of Anti-2019-nCoV(S1) - 2 (H4) antibody About the product Proteogenix has developed neutralizing antibodies against 2019-nCOV (as named by WHO when SARS-CoV-2 begun to spread). The Anti-2019-nCoV(S1)- 2(H4) antibody is an IgG1 isotype, especially targeting the S1 part of the Spike protein. This product is a human-origin monoclonal antibody expressed in a mammalian system, which has been validated in binding assays and infection assays. The molecular weight is 150 kDa. About Spike : the target The spike protein is a transmembrane viral fusion protein. Spike has a homotrimeric structure and each monomere is composed of two subunits: S1 and S2. The S1 part is carrying the Receptor Binding Domain (RBD), and the S2 part is responsible of the fusion of the virus with the cellular membrane. The RBD Part of S1 is binding the Angiotensin Converting Enzyme 2 (ACE2) in the organism. Proteogenix launched a panel of antibodies against SARS-CoV-2 spike and the nucleocapsid. Every of them can recognize specifically SARS-CoV-2 antigens without cross reactivity with other human coronaviruses. The antibody H4, blocks the RBD of the viral spike protein from binding to the cellular receptor, ACE2. This antibody is completely competitive with ACE2 for binding to RBD. It can bind simultaneously with the Anti-2019-nCoV(S1) – 1 (B38) antibody as these two antibodies are binding RBD in a different site. Neutralizing antibodies are very promising in antiviral defense against the coronavirus disease 2019 (COVID-19) pandemic. This product is suitable in all immunological methods. Research use only.